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Abstract
Kidney proximal tubules (PTs) contain a high density of mitochondria, which
are required to generate ATP to power solute transport. Mitochondrial dys-
function is implicated in the pathogenesis of numerous kidney diseases. Dam-
aged mitochondria are thought to produce excess reactive oxygen species
(ROS), which can lead to oxidative stress and activation of cell death path-
ways. MitoQ is a mitochondrial targeted anti-oxidant that has shown promise
in preclinical models of renal diseases. However, recent studies in nonkidney
cells have suggested that MitoQ might also have adverse effects. Here, using a
live imaging approach, and both in vitro and ex vivo models, we show that
MitoQ induces rapid swelling and depolarization of mitochondria in PT cells,
but these effects were not observed with SS-31, another targeted anti-oxidant.
MitoQ consists of a lipophilic cation (Tetraphenylphosphonium [TPP]) joined
to an anti-oxidant component (quinone) by a 10-carbon alkyl chain, which is
thought to insert into the inner mitochondrial membrane (IMM). We found
that mitochondrial swelling and depolarization was also induced by dodecylt-
riphenylphosphomium (DTPP), which consists of TPP and the alkyl chain,
but not by TPP alone. Surprisingly, MitoQ-induced mitochondrial swelling
occurred in the absence of a decrease in oxygen consumption rate. We also
found that DTPP directly increased the permeability of artificial liposomes
with a cardiolipin content similar to that of the IMM. In summary, MitoQ
causes mitochondrial swelling and depolarization in PT cells by a mechanism
unrelated to anti-oxidant activity, most likely because of increased IMM per-
meability due to insertion of the alkyl chain.
Introduction
Kidneys are highly aerobic organs and receive 20–25% of
cardiac output. Renal proximal tubules (PTs) are densely
packed with mitochondria, which are required to produce
ATP to power processes like solute transport. Kidney
mitochondria can be damaged by various insults –
including ischemia, sepsis and toxins – and mitochondrial
dysfunction is implicated in the pathogeneses of numer-
ous renal diseases (Che et al. 2014; Ralto and Parikh
2016; Bhargava and Schnellmann 2017). Mitochondria are
thought to produce reactive oxygen species (ROS) as a
by-product of oxidative phosphorylation (OXPHOS)
(Murphy 2009), and increased ROS generation in dam-
aged mitochondria can lead to oxidative stress and activa-
tion of cell death pathways (Halestrap 2010). Lowering
mitochondrial production or quenching ROS in disease
states might therefore be protective for cells. Since non-
specific anti-oxidants have proven disappointing
(Cocheme and Murphy 2010), and non-mitochondrial
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ROS can have important physiological roles (Sedeek et al.
2013), several anti-oxidant compounds have been devel-
oped that specifically target mitochondria, including SS
peptides, plastoquinone analogues (SkQ1/SkQR1), and
MitoQ (Tabara et al. 2014; Hall and Schuh 2016). SS
peptides, such as SS-31, are thought to interact with car-
diolipin in the inner mitochondrial membrane (IMM)
(Szeto and Birk 2014), whilst plastoquinone analogues
and MitoQ contain lipophilic cations and utilize the volt-
age gradient across the IMM (Dwm) generated by the
OXPHOS complexes to selectively accumulate into the
mitochondrial matrix at very high concentrations (Smith
and Murphy 2011; Jankauskas et al. 2012).
The lipophilic cation in MitoQ (Tetraphenylphospho-
nium [TPP]) is joined to an anti-oxidant component
(quinone) by a 10-carbon alkyl chain, which is thought
to insert into the IMM (Smith and Murphy 2010). Previ-
ous studies have shown that MitoQ accumulates into
mitochondria up to 100–1000 fold, and uptake into kid-
ney tissue has been confirmed in vivo (Smith and Mur-
phy 2010). Numerous recent animal studies have
suggested beneficial effects of MitoQ in various different
renal diseases, including: acute kidney injury (AKI)
induced by ischemia-reperfusion injury (IRI) (Dare et al.
2015), cold storage (Parajuli et al. 2012), sepsis (Lowes
et al. 2008) and cisplatin (Mukhopadhyay et al. 2012);
diabetic nephropathy (Chacko et al. 2010; Xiao et al.
2017); polycystic disease (Ishimoto et al. 2017); and
cystinosis (Galarreta et al. 2015). Due to the promising
protective effects in preclinical studies, MitoQ is now
being trialed in humans (Smith and Murphy 2010).
However, since MitoQ accumulates into mitochondria at
very high concentrations, the possibility remains that it
could have effects on mitochondrial function other than
on ROS levels, not all of which might be beneficial. For
example, a recent study has reported that MitoQ can
actually increase ROS production in some cancer cells,
and this is associated with a decrease in Dwm and mito-
chondrial DNA (mtDNA) copy number (Pokrzywinski
et al. 2016). Moreover, MitoQ has also been found to
induce autophagy in liver cells (Sun et al. 2017). Thus,
there is a pressing need to better understand the detailed
effects of MitoQ on mitochondrial function in kidney
tissue.
Mitochondria are complex and dynamic organelles,
capable of showing rapid changes in morphology
(Archer 2013). Live cell fluorescence imaging allows the
study of both the structure and function of mitochon-
dria, in their native environment within living tissue
(Duchen et al. 2003). Using this approach, we have
made the surprising discovery that MitoQ causes rapid
swelling and depolarization of mitochondria in kidney
PT cells, and that this effect is unrelated to its intended
anti-oxidant properties. Therefore, caution should be
exercised before transitioning this treatment to humans
with renal disease.
Materials and Methods
Unless stated otherwise, all reagents were purchased from
Sigma Aldrich. MitoQ was acquired from MedKoo Bio-
sciences and SS-31 from China Peptides.
Cell lines
Opossum kidney (OK) cells were a kind gift from the
group of Prof O. Devuyst (Physiology, University of
Zurich).
Animals
All experiments were performed on 8- to 12-week-old
male C57BL/6JRj mice.
Live cell imaging
Cells were seeded on Poly-L-lysine coated coverglasses
(Hecht-Assistent) and grown to 90% confluence. Imaging
was performed at 37°C in a buffer adjusted to pH 7.4
containing (in mmol/L): 138 NaCl, 5.6 KCl, 1.2
NaH2PO4, 2.6 CaCl2, 1.2 MgCl2, 10 Glucose, 4.2
NaHCO3, and 10 HEPES. Tetramethylrhodamine methyl
ester (TMRM) was purchased from Thermo Scientific and
was used at 50 nmol/L (excitation 555 nm). Confocal
microscopy was performed on a Leica SP8 inverse STED
3X.
Kidney cortex tissue slices were generated from freshly
externalized organs in mice anaesthetized with intra-peri-
toneal ketamine (0.065 g/kg) and xylazine (0.01 g/kg),
according to previously established protocols (Hall et al.
2009). After the removal of the capsule one pole of the
kidney was mounted and cut with a vibratome (Microm
HM 650 V, Thermo Scientific) into 250 lm thick sec-
tions. The tissue was kept until usage at 4°C in a physio-
logical buffer adjusted to pH 7.4 and gassed with
carbogen (95% O2/5% CO2), containing (in mmol/L):
118 NaCl, 4.7 KCl, 1.2 KH2PO4, 1.8 CaCl2, 1.44 MgSO4,
5 glucose, 10 NaHCO3, 10 HEPES, 5 sodium pyruvate,
2.5 sodium butyrate, and 2.5 sodium lactate. For live
imaging slices were mounted in a heated chamber (War-
ner Instruments) containing oxygenated buffer. Imaging
was performed with a Leica TCS SP8 Upright MP FLIM
Microscope equipped with an HC IRAPO L 25x/1.0 W
motCORR, WD: 2.6 mm and an Insight DS+ Dual (680–
1300 nm & 1041 nm) ultrafast NIR laser for multiphoton
excitation. Slices were incubated for 1 h before
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experiments in TMRM (50 nmol/L), which was excited at
850 nm.
Oxygen consumption
Cells were plated in Seahorse XFp 8 well culture plates
1 day prior to experiments. 1 h before analysis cells were
incubated at 37°C without CO2, in the same buffer used
for live imaging experiments. Cartridges were filled with
stock solutions of drugs dissolved in the buffer. After each
injection oxygen consumption was measured in 3 cycles,
each consisting of 2 min mixing followed by 2 min of
measurement. Values were normalized to the basal rate.
Liposomes
Liposomes were prepared according to a previously estab-
lished protocol (Firsov et al. 2016). Excess Calcein was
removed with dialysis (Slide-A-Lyzer MINI 7K, Thermo
Fisher Scientific) at 4°C for 48 h against a buffer contain-
ing 100 mmol/L KCl, 10 mmol/L Tris, and 10 mmol/L
MES, and adjusted to pH 7.4. The assay was performed
in dialysis buffer. Fluorescence was recorded every minute
at 528/20 nm (excitation 485/20 nm) using a Synergy 2
Multidetection reader (Biotek). Baseline was measured
with liposomes only (500 ng/mL) for 5 min before addi-
tion of drugs.
Study approval
All animal experiments were approved by the Zurich
Cantonal Veterinary Office.
Results
MitoQ causes acute swelling and
depolarization of mitochondria in kidney
proximal tubule cells
To investigate the effect of MitoQ on mitochondrial
structure and function we performed live confocal imag-
ing in PT-derived OK cells, since these retain many
important transport processes needed for normal kidney
function (Eshbach et al. 2017). Cells were loaded with the
voltage dependent dye TMRM to assess changes in Dwm
in real time. Application of MitoQ (500 nmol/L) caused
acute swelling of mitochondria (within 5 min) and rapid
dissipation of Dwm (Fig. 1A). In contrast, SS-31 at a 1000
fold higher dose (500 lmol/L) had no discernible impact
on mitochondrial structure/function (Fig. 1B), showing
that the response to MitoQ is unique to this compound,
rather than a common feature of all mitochondrial tar-
geted anti-oxidants.
MitoQ does not acutely inhibit oxygen
consumption
To explore whether MitoQ-induced mitochondrial swel-
ling is associated with changes in OXPHOS activity fur-
ther experiments were performed to assess the effect of
this compound on oxygen consumption rate (OCR). We
found that the addition of MitoQ (500 nmol/L) did not
acutely lower baseline OCR in OK cells, or change the
maximum OCR achieved in response to stimulation of
OXPHOS with the uncoupler Carbonyl cyanide-4-(tri-
fluoromethoxy)phenylhydrazone (FCCP) compared to
control cells (Fig. 1C). Thus, mitochondrial swelling and
depolarization induced by MitoQ occurs in the absence
of an acute decrease in OXPHOS function or capacity.
Mitochondrial toxicity from MitoQ is not
related to its anti-oxidant properties
Since SS-31 did not cause the same mitochondrial swel-
ling as MitoQ, even at a very high dose, we considered
that the toxic effects observed with the latter are probably
unrelated to its anti-oxidant activity. To investigate this,
we assessed the individual effects of different structural
components of MitoQ. We found that TPP (500 nmol/L),
the mitochondrial targeting cation of MitoQ, did not
induce any acute deleterious effects on mitochondria in
OK cells (Fig. 2A–B). However, dodecyltriphenylphospho-
mium (DTPP) (500 nmol/L), which consists of TPP plus
the carbon alkyl chain (but lacks the anti-oxidant qui-
none), caused acute mitochondrial swelling and depolar-
ization, identical to that induced by MitoQ (Fig. 2A–B).
These findings suggest that the toxic effect of MitoQ on
PT cell mitochondria is indeed unrelated to anti-oxidant
activity, and that the carbon alkyl chain plays an impor-
tant role.
MitoQ induces mitochondrial damage in
kidney cortex tissue
PT-derived cell lines are recognized to have limitations as
experimental models, and to be metabolically quite differ-
ent from PT cells in vivo (Hall et al. 2010; Nieskens and
Wilmer 2016). We therefore sought to know whether
MitoQ also induces a similar phenotype in native PTs. To
address this, we performed live imaging of freshly cut
250 lm sections of mouse kidney cortex, using multipho-
ton microscopy and protocols that we established in pre-
vious studies (Hall et al. 2009). MitoQ (50 lmol/L) was
applied directly to the tissue, under tightly controlled
experimental conditions. As in the OK cells, in response
to MitoQ we observed rapid swelling and depolarization
of mitochondria in PTs (Fig. 3). In contrast, over the
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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same time period mitochondria in control tissue
remained energized (Fig. 3). The effects of MitoQ were
recreated by the addition of DTPP (50 lmol/L) (Fig. 3).
Thus, we confirmed that MitoQ causes swelling and
depolarization of mitochondria in native PTs, and that
this effect is due to the major structural backbone of
the molecule, rather than the anti-oxidant quinone
component.
Dodecyltriphenylphosphomium increases
mitochondrial inner membrane permeability
We hypothesized that mitochondrial swelling and depo-
larization induced by DTPP could be explained by an
increase in IMM permeability, possibly due to insertion
of the carbon alkyl chain. To investigate this, and exclude
the potentially confounding effects of interactions with
native mitochondrial proteins, we performed experiments
using artificial liposomes containing 20% cardiolipin, to
model the consistency of the IMM. These were filled with
the fluorescent dye Calcein, release and unquenching of
which was then used as a readout of increase in mem-
brane permeability (Firsov et al. 2016). We observed an
abrupt increase in Calcein release with DTPP (Fig. 4),
suggesting that this compound can indeed directly
increase permeability of a membrane closely resembling
the IMM.
Discussion
The realization that mitochondrial dysfunction is central
to the pathogenesis of many kidney diseases, and that
Figure 1. MitoQ induces mitochondrial swelling in proximal tubular cells. (A) Live confocal imaging of proximal tubule-derived OK cells loaded
with the membrane potential dependent dye TMRM revealed that mitochondria swelled rapidly in response to MitoQ (500 nmol/L) before
subsequently depolarizing (scale = 10 lm). (B) In contrast, the antioxidant SS-31 at a 1000 fold higher dose (500 lmol/L) did not induce
changes in mitochondrial morphology or energization (scale = 10 lm). (C) Addition of MitoQ (500 nmol/L) did not acutely decrease baseline
oxygen consumption rate (OCR) in OK cells. Moreover, maximum OCR poststimulation of OXPHOS with the uncoupler FCCP (1 lmol/L) was
similar in both MitoQ and vehicle treated cells. OXPHOS was subsequently inhibited with cyanide (2 mmol/L). All values were normalized to
baseline OCR (n = 3 experiments).
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excess ROS generation within mitochondria can cause
oxidative stress, has led to an intensive search for novel
therapies that can lower ROS production specifically
within these organelles. MitoQ is an anti-oxidant that
accumulates selectively into mitochondria at very high
concentration, including in the kidney in vivo, and
numerous previous studies have suggested that it might
have beneficial effects in preclinical models of various dif-
ferent renal diseases. However, using live imaging and
both in vitro and ex vivo models, we have now shown
that MitoQ causes acute mitochondrial swelling and
depolarization in PT cells, and that this effect is due to
Figure 2. MitoQ-induced mitochondrial swelling is independent of its anti-oxidant function. (A) Chemical structures of MitoQ, DTPP and TPP.
(B) Live confocal imaging of OK cells loaded with TMRM revealed that DTPP (500 nmol/L) induced mitochondrial swelling and depolarization,
identical to that caused by MitoQ. In contrast, TPP (500 nmol/L), which lacks the carbon alkyl chain in DTPP, did not affect mitochondrial
morphology or energization state (scale = 10 lm).
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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increased IMM permeability, rather than anti-oxidant
activity. These findings suggest that caution should be
exercised before using this compound in renal patients.
Several different mitochondrial targeted anti-oxidants
have recently been developed that have generated much
excitement and stimulated ongoing trials in humans.
Whilst it seems clear that experimentally all of these
agents can lower ROS levels in mitochondria and prevent
oxidative stress, rather less attention has been paid to
potential off-target effects, which might be unique to each
compound. However, evidence is emerging that drug
specific effects on mitochondria can indeed occur. For
example, it has recently been reported that the protective
effects of SS peptides might be due in part to a favorable
Figure 3. MitoQ induces mitochondrial swelling in kidney tissue. Live high-resolution imaging with multiphoton microscopy of mouse kidney
cortex sections loaded with TMRM revealed that MitoQ (50 lmol/L) and DTPP (50 lmol/L) both induced acute swelling of mitochondria in
proximal tubules, followed subsequently by depolarization, demonstrated by redistribution of TMRM signal from mitochondria to the cytosol. In
contrast, no such adverse changes were observed in mitochondria in control experiments over the same time period (scale = 10 lm).
2018 | Vol. 6 | Iss. 7 | e13667
Page 6
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
MitoQ and Kidney Mitochondria E. M. Gottwald et al.
interaction with cardiolipin and cytochrome c (Birk et al.
2014). Given the generally dismal translational record of
putative new kidney treatments, and the occurrence of
unexpected toxic effects with previous attempts to phar-
macologically prevent oxidative stress (e.g., bardoxolone
in diabetic nephropathy (Van et al. 2015)), it is important
to understand in as much detail as possible exactly what
new drugs do to cell and organelle function in the kidney,
before moving to clinical studies.
We have made the surprising and unexpected finding
that MitoQ causes acute mitochondrial swelling and
depolarization in PT cells. Since this effect can be recre-
ated by DTPP, which lacks the quinone group of MitoQ,
but not by SS-31, it is highly unlikely to be related to
anti-oxidant activity. Moreover, we did not observe a
decrease in OCR, suggesting that OXPHOS function is
not inhibited. Acute mitochondrial swelling in pathologi-
cal states is often attributed to the opening of a large pore
in the IMM called the mitochondrial permeability transi-
tion pore (mPTP) (Biasutto et al. 2016). However, since
we showed that DTPP increased the permeability of lipo-
somes, which lack the components of the mPTP, a direct
effect on membrane properties is a more likely explana-
tion for mitochondrial swelling, which is biologically
plausible as the alkyl chain is thought to insert into the
IMM. Although some recent reports have raised concerns
about adverse effects of MitoQ, to the best of our knowl-
edge our study is the first to directly demonstrate rapid
mitochondrial swelling and dissipation of Dwm in mam-
malian cells, and to provide a clear mechanistic explana-
tion for this effect. Of note, a previous group reported
evidence of mitochondrial swelling induced by DTPP in
isolated yeast mitochondria (Trendeleva et al. 2012).
In striking contrast to scant reports of toxicity, numer-
ous studies have reported beneficial effects for MitoQ,
and we believe there are several potential explanations for
this apparent discrepancy. First, many studies have relied
on methodologies other than live imaging, and have natu-
rally focused predominantly on alterations in ROS levels,
so may have missed off-target effects on mitochondrial
morphology and energization. Remarkably, despite the
fact that MitoQ causes severe mitochondrial swelling,
OCR measurements suggested that OXPHOS can con-
tinue under these conditions. Importantly, this means
that MitoQ and DTPP would not be identified as mito-
chondrial toxins if relying on this frequently used readout
alone, and nicely demonstrates that live imaging can add
substantial information to standard biochemical assays.
Second, it could be that the concentration of MitoQ in
renal mitochondria in vivo may not reach a sufficiently
high level to cause toxicity. We are not aware of any pre-
vious kidney studies that have reported blood concentra-
tions of MitoQ to directly relate our data to, but we
found clear evidence of deleterious effects in vitro at a
concentration of only 500 nmol/L. Moreover, evidence
suggests that MitoQ does not undergo significant modifi-
cation or metabolism in vivo (Smith and Murphy 2010).
Third, there could be some beneficial effects of increasing
IMM permeability in cells in disease states. For example,
since ROS production is thought to be dependent on
energization state (Murphy 2009), lowering Dwm might
decrease ROS generation (so-called partial uncoupling
(Johnson-Cadwell et al. 2007)). However, this has to be
balanced with the risk of triggering other Dwm-dependent
processes, like mitophagy (Kim and Lemasters 2011).
Finally, the well-recognized issue of publication bias is
likely to play a role, as there is generally far more interest
in reporting new treatments than new toxins.
In summary, we have found that MitoQ can cause sig-
nificant mitochondrial toxicity in kidney tissue indepen-
dent of anti-oxidant activity, and in the absence of a
decrease in OCR. These surprising findings underline the
Figure 4. DTPP increases permeability in lipid vesicles resembling the mitochondrial inner membrane. (A) DTPP increased Calcein leakage from
artificial liposomes (500 ng/mL) with a cardiolipin content of 20%, resembling the inner mitochondrial membrane. (B) Calcein fluorescence
values at 4 min postdrug addition, normalized to baseline, one-way ANOVA, post hoc Dunnett’s multiple comparison test (** = P < 0.01,
n = 3).
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point that drugs can have unexpected side-effects inde-
pendent of their intended mechanism of action, and pro-
vide further evidence that live imaging can play an
important role in comprehensively phenotyping how
mitochondria respond to pharmacological interventions.
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